Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. (NASDAQ: MGRX) is frequently in the news for developments across telemedicine-based wellness, digital assets, and capital markets activity. The company describes itself as focused on developing, marketing, and selling men’s and women’s health and wellness products and services via secure telemedicine platforms under the MangoRx and PeachesRx brands, and its announcements reflect this multi-faceted strategy.
News updates about Mangoceuticals often highlight new or expanded programs on its telehealth platforms, including offerings related to erectile dysfunction, hair growth, hormone replacement therapies, and weight management. The company has issued releases describing MangoRx Direct and PeachesRx Direct weight-management programs, as well as the launch of PeachesRx as a women’s telehealth brand focused initially on GLP-1–based weight management solutions.
Investors following MGRX news will also see coverage of Mangoceuticals’ work on MGX-0024, a patented antiviral compound described as a blend of natural polyphenols and zinc evaluated in poultry field studies for respiratory diseases. Additional headlines have addressed the company’s acquisition of intellectual property from Smokeless Technology Corp. related to stimulant and functional pouches, and prior announcements concerning exclusive rights to the plant-based nutraceutical Diabetinol, followed by a later filing describing the mutual rescission of that agreement.
Mangoceuticals’ news flow further includes updates on its Solana-focused digital asset treasury strategy through Mango DAT, LLC in partnership with Cube Group, as well as financing transactions such as private placements, registered direct offerings, warrant exercises, and equity line drawdowns. For readers tracking MGRX, this news page provides a centralized view of company-issued press releases and related market-moving disclosures. Bookmark this page to review new Mangoceuticals announcements, product and program descriptions, and SEC-reported events as they are released.
Mangoceuticals Inc. (NASDAQ:MGRX) is expanding its presence in the health and wellness sector through innovative product offerings. The company's flagship product, Mango, offers ED treatment in two versions: Sildenafil Mango and Tadalafil Mango, featuring fast-acting dissolvable tablets with unique formulations.
The company's portfolio includes:
- Prime by MangoRx: A telehealth-enabled testosterone replacement therapy using Kyzatrex™, an FDA-approved oral testosterone capsule
- Grow by MangoRx: A comprehensive hair loss treatment combining Minoxidil, Finasteride, Biotin, and Vitamin D3
- Slim by MangoRx: An oral dissolving Semaglutide tablet for weight loss
- Diabetinol®: A patented plant-based nutraceutical for metabolic health
The company has also launched PeachesRx, a women's wellness brand, expanding their reach beyond men's health to create a comprehensive wellness ecosystem.
Mangoceuticals (NASDAQ: MGRX) has secured exclusive licensing and distribution rights for Diabetinol® in the United States and Canada, entering the $33.66 billion diabetes and metabolic health market. Diabetinol® is a patented plant-based nutraceutical derived from citrus peel, clinically proven to improve insulin sensitivity and metabolic function.
The product will be distributed in multiple formats including capsules, beverages, pouches, cookies, and gummies through direct-to-consumer channels, online retailers, brick-and-mortar stores, and affiliate marketing. The expansion targets the growing diabetes crisis, with over 30 million Americans suffering from type 2 diabetes and 97.6 million adults having prediabetes.
The company positions Diabetinol® as a more affordable alternative for individuals who cannot access or tolerate GLP-1 medications, addressing a significant market need as U.S. diabetes-related healthcare costs exceed $400 billion annually.
Mangoceuticals (NASDAQ: MGRX) has announced the launch of PeachesRx, a women's telehealth platform focusing on health and wellness products, initially specializing in GLP-1 receptor agonists for weight loss treatment. The platform will operate through www.PeachesRx.com, offering HIPAA-compliant telemedicine services.
The company is targeting the expanding GLP-1 market, where approximately 70% of weight loss prescriptions are written for women. The global GLP-1 market for weight management is projected to exceed $48 billion by 2030. The women's health market, valued at $49.33 billion in 2024, is expected to reach $68.53 billion by 2030, growing at a 5.1% CAGR.
Studies indicate that over 60% of telehealth users are female, positioning PeachesRx to capture this market segment. The company plans to expand beyond GLP-1 treatments into broader wellness categories, including sexual health, hair growth, and hormone therapy solutions.
Mangoceuticals (NASDAQ: MGRX) is advancing research on respiratory illness prevention technology, focusing on combating avian influenza (H5N1) in the poultry industry. The company has engaged Vipragen Biosciences to conduct efficacy studies for an antiviral solution using their patented technology acquired from IntraMont Technologies.
The company is developing a water-based application for poultry using Generally Recognized as Safe (GRAS) ingredients. Phase I animal studies have shown significant efficacy in reducing lung viral load, and Phase II studies are ongoing. The solution aims to address the devastating impact of avian flu, which has led to the culling of over 148 million birds in the US since 2022 and caused egg prices to reach $4.15 per dozen as of December 2024, with a projected 20% increase in 2025.
The company targets the global poultry market, projected to reach $375.41 billion by 2030, offering a potential non-pharmaceutical preventive solution for the industry.
Mangoceuticals (NASDAQ: MGRX) has announced significant progress in its H1N1 efficacy study, reporting a substantial reduction in viral load during Phase 1 animal trials. The company is now advancing to the next research stage while simultaneously expanding its focus to include H5N1 (Avian Influenza) studies.
The research, conducted by Vipragen Biosciences in India, utilizes Mangoceuticals' proprietary formulation combining advanced polyphenol and zinc chemistry. The H5N1 cohort will run concurrently with the ongoing H1N1 study, demonstrating the company's commitment to addressing multiple respiratory illness threats.
The company plans to disclose final results after completing the studies and securing proper intellectual property protections through provisional filings.
Mangoceuticals (NASDAQ: MGRX) has entered into an exclusive Master Distribution Agreement with Propre Energie for Dermytol®, a clinically proven skincare treatment targeting hyperpigmentation. The agreement grants MGRX exclusive rights to market, sell, and distribute Dermytol® across North and South America.
Dermytol® is an advanced, plant-based formula proven more effective than Kojic acid at reducing melanin production while causing less damage to skin cells. The product utilizes a proprietary blend of ingredients including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera.
The partnership targets the growing global skincare market, projected to reach $218 billion by 2029 with a 3.61% CAGR. The plant-based skincare segment specifically is expected to grow from $789.75 million in 2023 to $1.62 billion by 2033, representing a 7.5% CAGR.
Mangoceuticals (NASDAQ: MGRX) has acquired patent WO 2023/086647 PCT/US2022/049857 for mushroom-derived compositions and treatment methods. The patent covers nutraceutical formulations from functional mushrooms including Cordyceps sinensis, Ganoderma lucidum (Reishi), and Hericium erinaceus (Lion's Mane), designed to enhance immune function, cognitive performance, mood, and provide adaptogenic benefits.
The company plans to develop new wellness products leveraging this patent, including dietary supplements and functional foods. The acquisition aligns with the growing functional mushroom market, which is valued at $32.41 billion in 2024 and projected to reach $48.59 billion by 2029, with a CAGR of 8.44% according to Mordor Intelligence.
Mangoceuticals (NASDAQ: MGRX) has initiated an investigation into potential stock manipulation following its October 16, 2024 reverse stock split. The company identified suspicious trading patterns and an unusual surge in shareholder accounts. The Depository Trust Company (DTC) requested 213,327 additional shares for fractional share 'round-up', representing about 9% of MangoRx's 2.4 million post-split outstanding shares.
Prior to the split, MangoRx had approximately 5,000 shareholders, but trading patterns suggest a potential increase of over 200,000 accounts post-split. The company observed numerous high-frequency single-share transactions around the split date. CEO Jacob Cohen has denied DTC's request pending investigation completion. MangoRx notes similar patterns to those reported by Upexi Inc. (NASDAQ:UPXI), which experienced comparable irregularities in their recent reverse stock split.
Mangoceuticals (NASDAQ: MGRX) has regained full compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq on October 30, 2024, stating that its common stock maintained a closing bid price at or above $1.00 per share for 10 consecutive business days, meeting the requirements of Nasdaq Listing Rule 5550(a)(2). With this compliance achievement, the listing matter is now closed.
MangoRx (NASDAQ: MGRX), a company specializing in men's health and wellness products via telemedicine, has announced the formation of a Strategy and Alternatives Committee. The company's Board of Directors has initiated a process to evaluate potential strategic alternatives aimed at maximizing shareholder value.
These alternatives may include mergers, acquisitions, divestitures, business combinations, entry into new lines of business, expansions, and joint ventures. This initiative will run parallel to MangoRx's current operations. The company plans to consult with financial and legal advisors to consider a wide range of strategic, operational, and financial options.
MangoRx has not set a timeline for completing this review process and does not intend to provide further comments unless necessary. The company emphasizes that there is no guarantee that this strategic review will result in any specific transaction or outcome.